Caplin Point Laboratories Limited (CAPLIPOINT)
₹2,301.30 -0.02% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Caplin Point's revenue was ₹610 Cr (+19.6% year on year, +1.7% on the previous quarter), and net profit ₹179 Cr (+18.8% year on year); the operating margin was 35.0%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹610 | +19.6% | +1.7% |
| Operating profit | ₹213 | +20.1% | +4.6% |
| Net profit | ₹179 | +18.8% | +3.5% |
| EPS (₹) | 23.27 | +15.8% | +4.0% |
| Operating margin | 35.0% | — | — |
CAPLIPOINT delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 49.08% of the CAPLIPOINT shares traded on NSE were taken to delivery, against the stock's own 20-session average of 37.19%. Delivery was unusually high while the price barely moved (-0.02%). Volume was 0.3 times its average, well below normal.
Delivery in the last 5 sessions: 40.2% · 43.5% · 38.5% · 42.8% · 49.1%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Caplin Point Laboratories Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. Issued by the Registrar and Share Transfer Agent (RTA), Integrated Registry Management Services Private Limited, the certificate covers the quarter and half-year ended September 30, 2026. The RTA confirmed that securities received for dematerialisation were duly processed, confirmed to exchanges, and cancelled within the prescribed 15-day limit. This is a standard administrative compliance filing with no impact on corporate fundamentals.
- Regulation 74(5) demat confirmation certificate filed for the quarter ended September 30, 2026
- Issued by RTA Integrated Registry Management Services Private Limited on October 3, 2026
- Confirmation that dematerialisation certificates were mutilated and cancelled within 15 days of receipt
Caplin Point Laboratories has issued a communication under Regulation 36(1)(b) of SEBI LODR Regulations to shareholders whose email addresses are not registered. The communication provides access weblinks to the Notice and Annual Report for FY 2025-26. The 35th Annual General Meeting is scheduled to be held on September 25, 2026, at 10:00 AM IST through Video Conferencing.
- 35th Annual General Meeting scheduled for September 25, 2026, at 10:00 AM IST
- Meeting to be conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM)
- Weblink dispatched to unregistered email shareholders for FY 2025-26 Annual Report access
Caplin Point Laboratories has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, supported by a limited assurance report from Alagar & Associates LLP. The disclosure confirms that 100% of the company's formulation turnover is exported across 57 international markets. Operating assets include 4 manufacturing units and 5 R&D centres with a workforce of 2,877 total personnel. This is a standard statutory compliance filing with no immediate impact on financials or business outlook.
- 100% of product turnover generated from export markets across 57 countries
- Operating footprint consists of 4 manufacturing units and 5 R&D centres in India
- Total headcount stands at 2,877 employees (2,249 permanent) with 39% female workforce participation
- Permanent employee turnover rate stood at 36.93% for FY 2025-26 compared to 32.52% in FY 2024-25
Caplin Point Laboratories has issued the notice for its 35th Annual General Meeting scheduled for September 25, 2026, via video conferencing. Key ordinary business includes voting on a final dividend of ₹4 per equity share (200%), bringing the total dividend for FY26 to ₹8 per share (400%). The record date and e-voting cut-off date is September 18, 2026. The company is also seeking shareholder approval for the re-appointment of Managing Director Dr. Sridhar Ganesan and the appointment of CFO Mr. D Muralidharan as Whole Time Director for 2-year tenures.
- 35th AGM scheduled for Friday, September 25, 2026 at 10:00 AM IST via VC/OAVM
- Final dividend proposed at ₹4 per share (200%), taking total FY26 dividend to ₹8 per share (400%)
- Record date and e-voting cut-off date fixed as September 18, 2026
- Re-appointment of Dr. Sridhar Ganesan as MD for 2 years with base salary of ₹55,20,000 p.a.
- Appointment of Mr. D Muralidharan as Whole Time Director for 2 years with base salary of ₹62,37,600 p.a.
Caplin Point Laboratories responded on September 02, 2026, to an NSE clarification query dated September 01, 2026, regarding a significant increase in trading volume. The company stated that it has complied with Regulation 30 of SEBI LODR Regulations and disclosed all material events. It confirmed that no price-sensitive information has been withheld and that the recent surge in trading volume is purely market-driven.
- NSE sought clarification on September 01, 2026, regarding a significant increase in equity trading volume.
- Company clarified on September 02, 2026, that all material events have been duly disclosed under Regulation 30.
- Company confirmed that no price-sensitive information is withheld and volume movements are purely market-driven.
Caplin Point Laboratories announced that its subsidiary, Caplin One Labs Limited (COL), has received confirmation of Good Manufacturing Practices (GMP) compliance from INVIMA (Colombia). The approval applies to its manufacturing unit in Kakkalur, Tiruvallur District, Tamil Nadu. The clearance covers oncology drug products across sterile lyophilized powder for injection (vials) and non-sterile tablets and hard capsules. Formal certification is expected in due course, expanding the company's regulatory access in Latin America.
- Subsidiary Caplin One Labs received GMP compliance confirmation from Colombia's regulator INVIMA on September 01, 2026
- Approval covers oncology manufacturing at the Kakkalur, Tamil Nadu facility
- Approved dosage forms include sterile lyophilized powder for injection (vials) and non-sterile tablets/capsules
- Formal certificate from INVIMA is expected to follow in due course
The US FDA completed an unannounced inspection of Caplin Steriles' (subsidiary of Caplin Point) injectable and ophthalmic facility at Gummidipoondi between August 13 and August 21, 2026. The inspection concluded with the issuance of Form 483 with 10 observations. The company confirmed the observations are procedural in nature, do not involve data integrity issues, and contain no repeat citations. Caplin Steriles is preparing a comprehensive response within the stipulated regulatory timeline.
- Unannounced US FDA inspection conducted from August 13, 2026, to August 21, 2026.
- Form 483 issued with 10 procedural observations.
- Zero data integrity issues and zero repeat observations identified by the agency.
- Company committed to submit a detailed corrective response within the stipulated regulatory timeframe.
Caplin Point Laboratories has released the transcript for its Q1 FY27 earnings conference call held on August 12, 2026. The call reviewed financial performance for the quarter ended June 30, 2026, where the company recorded revenue of ₹610.36 crore and net profit of ₹179.09 crore. The full transcript has been made accessible on the company's official website as per regulatory compliance requirements.
- Earnings call transcript published for the quarter ended June 30, 2026
- Investor conference call was conducted on August 12, 2026
- Filing made pursuant to Regulation 30(6) of SEBI LODR Regulations, 2015
- Full transcript made available via company website link
Caplin Point Laboratories has released the audio recording of its Q1 FY 2026-27 earnings call held on August 12, 2026. The company currently reports a TTM revenue of ₹2,187 Cr and a strong net profit of ₹650 Cr. With an operating profit margin of 34.8% and a debt-free balance sheet (D/E 0.00), the call likely covers progress on the US front-end expansion and the upcoming Mexico facility. This filing is a standard regulatory requirement following the announcement of quarterly results.
- Earnings call for Q1 FY 2026-27 conducted on August 12, 2026, at 16:30 IST
- Company maintains a high TTM Operating Profit Margin of 34.8%
- Mexico facility (Triwin Pharma) targeted for FY 2027 commissioning with 50 million units capacity
- US front-end expansion includes 15+ more products planned for launch in FY26
Caplin Point Laboratories reported a strong start to FY27 with consolidated revenue growing 19.6% YoY to ₹610.36 cr. Consolidated Net Profit increased by 18.8% YoY to ₹179.09 cr, reflecting stable operational efficiency. The Board recommended a final dividend of ₹4 per share (200%), bringing the total dividend for FY26 to ₹8 per share. Additionally, the company ensured leadership continuity by re-appointing Dr. Sridhar Ganesan as Managing Director for two years.
- Consolidated Revenue from operations rose to ₹610.36 cr in Q1 FY27 from ₹510.22 cr in Q1 FY26.
- Consolidated Net Profit for the quarter stood at ₹179.09 cr compared to ₹150.76 cr in the previous year's corresponding quarter.
- Recommended a final dividend of ₹4 per equity share of ₹2 face value for FY26.
- Managing Director Dr. Sridhar Ganesan re-appointed for a 2-year term effective August 25, 2026.
- CFO Mr. D. Muralidharan appointed as Whole-Time Director for a 2-year term effective August 12, 2026.
Caplin Point Laboratories has approved the re-appointment of Dr. Sridhar Ganesan as Managing Director for a two-year term effective August 25, 2026. Additionally, the current Chief Financial Officer, Mr. D. Muralidharan, has been elevated to the Board as a Whole-Time Director for a two-year term while continuing his role as CFO. These appointments ensure leadership continuity as the company pursues its FY26-27 expansion plans in the US, Mexico, and China. The company maintains a strong financial profile with a TTM PAT of Rs 650 Cr and an operating margin of 34.8%.
- Dr. Sridhar Ganesan re-appointed as Managing Director for a 2-year term from August 25, 2026, to August 24, 2028
- Mr. D. Muralidharan appointed as Whole-Time Director for 2 years starting August 12, 2026, while retaining CFO duties
- Mr. Muralidharan has served as the company's CFO since February 19, 2016, providing over 8 years of financial leadership
- Dr. Ganesan brings over 35 years of global pharmaceutical experience to his continued role as MD
- Appointments are subject to shareholder approval at the upcoming Annual General Meeting
Caplin Point Laboratories reported a strong start to FY27 with consolidated revenue growing 19.6% YoY to ₹610.36 Cr. Net profit for the quarter rose 18.8% YoY to ₹179.09 Cr, maintaining a robust net margin profile. The board recommended a final dividend of ₹4 per share, which, combined with the previously paid interim dividend, brings the total FY26 payout to ₹8 per share. Additionally, the company ensured leadership continuity by re-appointing Dr. Sridhar Ganesan as Managing Director for a two-year term.
- Consolidated Revenue for Q1 FY27 increased to ₹610.36 Cr from ₹510.22 Cr in the previous year's quarter.
- Consolidated Net Profit grew 18.8% YoY to ₹179.09 Cr, resulting in a Basic EPS of ₹23.27.
- Recommended a Final Dividend of ₹4 per share (200% of face value), payable by October 24, 2026.
- Total dividend for FY26 stands at ₹8 per share including the ₹4 interim dividend already paid.
- Re-appointed Dr. Sridhar Ganesan as MD and appointed CFO Mr. D. Muralidharan as Whole-Time Director for 2-year terms.
Caplin Point Laboratories has fixed September 18, 2026, as the record date to determine shareholder eligibility for the final dividend of FY 2025-26. The dividend is subject to approval at the company's 35th Annual General Meeting (AGM) scheduled for September 25, 2026. This follows a strong financial year where the company reported a TTM PAT of Rs 650 Cr and maintained high operating margins of 34.8%. Investors must hold the equity shares (Face Value Rs 2) by the record date to be eligible for the payout.
- Record date for final dividend eligibility set for September 18, 2026
- 35th Annual General Meeting (AGM) scheduled for September 25, 2026
- Dividend pertains to the full Financial Year 2025-26
- Company reported FY26 revenue of Rs 2,187.26 Cr and PAT of Rs 649.99 Cr
Caplin Point Laboratories reported a steady Q1 FY27 with consolidated revenue growing 19.6% YoY to ₹610.36 cr. Net profit attributable to owners increased 15.8% YoY to ₹176.91 cr, maintaining strong profitability with a PBT margin of approximately 36.9%. The board recommended a final dividend of ₹4 per share, bringing the total dividend for FY26 to ₹8 (400% of face value). Key leadership remains stable with the re-appointment of Dr. Sridhar Ganesan as MD and the elevation of CFO Mr. D. Muralidharan to Whole-Time Director.
- Consolidated revenue from operations grew 19.6% YoY to ₹610.36 cr from ₹510.22 cr in Q1 FY26
- Net profit attributable to owners rose 15.8% YoY to ₹176.91 cr compared to ₹152.80 cr in the previous year
- Recommended a final dividend of ₹4 per share (200%), totaling ₹8 for FY26 including the interim dividend
- Managing Director Dr. Sridhar Ganesan re-appointed for a 2-year term effective August 25, 2026
- Consolidated Profit Before Tax (PBT) stood at ₹225.22 cr, representing a 22.1% YoY increase
Caplin Point Laboratories has scheduled its post-results conference call for August 12, 2026, at 4:30 PM IST to discuss financial performance for the quarter ended June 30, 2026. The call will feature top management, including the Chairman and Managing Director. This follows a strong FY26 where the company achieved a TTM revenue of ‡2,187 Cr and maintained high operating margins of 34.8%. Investors will be looking for updates on the 15+ planned US product launches and the progress of the Mexico facility targeted for FY27.
- Earnings conference call scheduled for August 12, 2026, at 04:30 PM IST
- Discussion will focus on the financial results for the quarter ended June 30, 2026
- Management representation includes Chairman C.C. Paarthipan and MD Dr. Sridhar Ganesan
- Company reported a TTM PAT of ‡650 Cr and EPS of ‡84.36 leading into this quarter
- Current market capitalization stands at ‡20,135 Cr with a P/E of 31.0
Financial Performance
Revenue Growth by Segment
Total consolidated revenue grew 15.5% YoY to INR 2,034 Cr in FY25. Revenue from operations increased 14.4% to INR 1,937.47 Cr. The US front-end entity generated initial revenue of $3.2 million (approx. INR 26.8 Cr) within its first 8 months of operation.
Geographic Revenue Split
Predominantly focused on emerging markets of Latin America (LATAM) and Africa. The company is expanding into regulated markets, with the US front-end showing early success and future revenue expected from Canada, Mexico, and Australia in FY26–27.
Profitability Margins
Gross Profit grew 20.3% to INR 1,167 Cr. Operating Profit Margin stood at 49.81% (consolidated), while Net Profit Margin improved to 27.93% in FY25 from 27.24% in FY24.
EBITDA Margin
EBITDA grew 20.2% YoY to INR 743 Cr, representing an EBITDA margin of 38.3% on revenue from operations, up from 36.5% in FY24.
Capital Expenditure
The company acquired 5.5 acres of land in Mexico for INR 19.85 Cr (USD 2.237 million) and plans to invest up to INR 133 Cr (USD 15 million) in a new manufacturing facility targeted for commissioning in FY 2027.
Credit Rating & Borrowing
The company is debt-free with a Debt-Equity Ratio listed as Not Applicable (NA). It maintains a strong cash position of INR 1,180 Cr, representing 58% of FY25 revenue.
Operational Drivers
Raw Materials
Peptides, Key Starting Materials (KSMs) for Biosimilars, and Active Pharmaceutical Ingredients (APIs).
Import Sources
China (specifically for Peptides and KSMs) and India.
Key Suppliers
Not disclosed in available documents; referred to as quality partners in India and China.
Capacity Expansion
Mexico facility (Triwin Pharma) planned with an initial capacity of 50 million units per annum for Suppositories and Topicals by FY 2027. Current manufacturing is a mix of 60% in-house and 40% outsourced.
Raw Material Costs
Cost of Goods Sold (COGS) is approximately 39.7% of revenue (calculated from Gross Profit of INR 1,167 Cr on INR 1,937 Cr revenue). Procurement strategy focuses on asset-light outsourcing and backward integration through new API entities.
Logistics & Distribution
The company uses its own distribution networks in underserved markets to ensure faster cash cycles and receivable control.
Strategic Growth
Expected Growth Rate
15.50%
Growth Strategy
Achieved through own-label front-end expansion in the US (24 products launched, 15+ more planned for FY26), greenfield expansion in Mexico (FY27), and a 'Second Innings' in China focusing on asset-light outsourcing of Peptides and Biosimilar KSMs. The company is also targeting 7 Pre-Filled Syringe filings in FY26.
Products & Services
Finished dosage forms, Injectables, Ophthalmics, RTU (Ready-to-Use) bags, Pre-filled syringes, Suppositories, and Topicals.
Brand Portfolio
Caplin Steriles (US Subsidiary), Triwin Pharma (Mexico Subsidiary).
New Products/Services
Launched RTU Bags, Ophthalmic Emulsions, and Injectable Emulsions. 15+ more products planned for US launch in FY26.
Market Expansion
Targeting Canada, Mexico, and Australia for revenue generation in FY26–27. Mexico facility targeted for FY27 commissioning.
Market Share & Ranking
Ranked on Forbes 'Asia’s 200 Best Under a Billion' list for the 7th time in 10 years.
Strategic Alliances
Collaborates with partners for ANDA filings (53 total filed with partners/acquired) and tied up with top 7 wholesalers and 24 direct buyers in the US.
External Factors
Industry Trends
Indian pharma market projected to reach $13.48bn in 2025 with a 5.31% CAGR through 2030. Shift toward complex generics, oncology drugs, and digital health innovations.
Competitive Landscape
Focuses on difficult-to-manufacture and niche products (RTU bags, pre-filled syringes) to differentiate from generic competition.
Competitive Moat
Durable advantage through own distribution networks in underserved markets and an 'always-ready' regulatory posture with USFDA, EU-GMP, and ANVISA approvals.
Macro Economic Sensitivity
Sensitive to global growth shocks and US tariff policies which are described as a 'major negative shock' to growth.
Consumer Behavior
Rising urbanization and healthcare investments in LATAM and Africa are driving increased pharmaceutical demand.
Geopolitical Risks
Exposure to political instability in LATAM and Africa; mitigated by first-mover advantage and deep market moats.
Regulatory & Governance
Industry Regulations
Adheres to USFDA, EU-GMP, ANVISA (Brazil), and INVIMA (Colombia) standards. Maintains 'always-ready' posture to address regulatory observations swiftly.
Environmental Compliance
Committed to ESG best practices with a focus on low carbon footprint and women empowerment; specific costs not disclosed.
Risk Analysis
Key Uncertainties
Regulatory compliance risks, supply chain disruptions, and currency volatility in emerging markets.
Geographic Concentration Risk
High concentration in Latin America and Africa, though US front-end is scaling to diversify revenue.
Third Party Dependencies
40% dependency on outsourced manufacturing partners in India and China.
Technology Obsolescence Risk
Mitigated by 5 dedicated R&D facilities and focus on complex injectable/ophthalmic pipelines.
Credit & Counterparty Risk
Debtors Turnover Ratio of 3.30 (Consolidated). Risk mitigated by own distribution and negative working capital model in LATAM.
